Evidence map›Paper›PMID 32784645›Full record

ArticlePolymers2020

3D Printing of Tunable Zero-Order Release Printlets.

Fabrizio Fina, Alvaro Goyanes, Martin Rowland, Simon Gaisford, Abdul W Basit

Abstract read
In one paragraph

Article in Polymers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Rising role of 3D-printing in delivery of therapeutics for infectious disease.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fabrizio FinaDepartment of Pharmaceutics, UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK.ORCID 0000-0002-5496-7829
Alvaro GoyanesDepartment of Pharmaceutics, UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK.ORCID 0000-0002-3378-6797
Martin RowlandPfizer Ltd., Drug Product Design, Discovery Park, Ramsgate Road, Sandwich CT13 9ND, UK.
Simon GaisfordDepartment of Pharmaceutics, UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK.ORCID 0000-0003-1000-3208
Abdul W BasitDepartment of Pharmaceutics, UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK.ORCID 0000-0002-5368-6603

Funding

Engineering and Physical Sciences Research Council EP/L01646X
6 · The paper itself

Abstract

Zero-order release formulations are designed to release a drug at a constant rate over a prolonged time, thus reducing systemic side effects and improving patience adherence to the therapy. Such formulations are traditionally complex to manufacture, requiring multiple steps. In this work, fused deposition modeling (FDM) 3D printing was explored to prepare on-demand printlets (3D printed tablets). The design includes a prolonged release core surrounded by an insoluble shell able to provide zero-order release profiles. The effect of drug loading (10, 25, and 40%

Indexed as

3D printed drug productscomputer aided drug design and deliverycontrolled releasedigital pharmaceuticsgastrointestinal modified release drug deliveryhealth and pharmaceutical sciencespersonalized medicinesprinting pharmaceuticalsthree dimensional printing

Identifiers

PMID32784645
PMCPMC7465712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.